FDA issued a Warning Letter to Surmasis Pharmaceutical on 11/6/2018 as a result of this inspection.
483 Surmasis Pharmaceutical Mar 2018

483 Surmasis Pharmaceutical Mar 2018

Brett Havranek FDA, Michele Obert FDA$119.00 - Available Now

FDA investigators audited the Surmasis Pharmaceutical - Des Moines, IA, United States facility and issued inspectional observations (via FDA 483) on 01 Mar 2018.

Product details

  • Category: Human Drugs
  • Inspection end: 01 Mar 2018
  • Location: Des Moines, United States
  • FEI: 3011596846
Add To Cart